In patients having transjugular intrahepatic portosystemic shunt, rifaximin prevented overt hepatic encephalopathy.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 34224266.
- Also identified by DOI 10.7326/ACPJ202107200-078.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bureau C, Thabut D, Jezequel C, et al. <b>The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial.</b> Ann Intern Med. 2021;174:633-40. 33524293.
Medical subject headings
- Hepatic Encephalopathy
- Portasystemic Shunt, Transjugular Intrahepatic